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http://www.biomedcentral.com/1471-2296/13/56RESEARCH ARTICLE Open AccessDeprescribing medication in very elderly patients
with multimorbidity: the view of Dutch GPs. A
qualitative study
Jan Schuling*, Henkjan Gebben, Leonardus Johannes Gerardus Veehof and Flora Marcia Haaijer-RuskampAbstract
Background: Elderly patients with multimorbidity who are treated according to guidelines use a large number of
drugs. This number of drugs increases the risk of adverse drug events (ADEs). Stopping medication may relieve
these effects, and thereby improve the patient’s wellbeing. To facilitate management of polypharmacy
expert-driven instruments have been developed, sofar with little effect on the patient’s quality of life. Recently,
much attention has been paid to shared decision-making in general practice, mainly focusing on patient
preferences. This study explores how experienced GPs feel about deprescribing medication in older patients with
multimorbidity and to what extent they involve patients in these decisions.
Methods: Focusgroups of GPs were used to develop a conceptual framework for understanding and categorizing
the GP’s view on the subject. Audiotapes were transcribed verbatim and studied by the first and second author.
They selected independently relevant textfragments. In a next step they labeled these fragments and sorted them.
From these labelled and sorted fragments central themes were extracted.
Results: GPs discern symptomatic medication and preventive medication; deprescribing the latter category is seen
as more difficult by the GPs due to lack of benefit/risk information for these patients.
Factors influencing GPs’deprescribing were beliefs concerning patients (patients have no problem with
polypharmacy; patients may interpret a proposal to stop preventive medication as a sign of having been given up
on; and confronting the patient with a discussion of life expectancy vs quality of life is ‘not done’), guidelines for
treatment (GPs feel compelled to prescribe by the present guidelines) and organization of healthcare (collaboration
with prescribing medical specialists and dispensing pharmacists.
Conclusions: The GPs’ beliefs concerning elderly patients are a barrier to explore patient preferences when
reviewing preventive medication. GPs would welcome decision support when dealing with several guidelines for
one patient. Explicit rules for collaborating with medical specialists in this field are required. Training in shared
decision making could help GPs to elicit patient preferences.
Keywords: General practice, Frail elderly, Polypharmacy, Withdrawing treatment, Preventive therapy, Quality of lifeBackground
Elderly patients with multimorbidity who receive treat-
ment according to professional guidelines for their re-
spective diseases use a large number of drugs. Preventive
medication, such as for cardiovascular risk management
and the treatment of diabetes mellitus, contributes sub-
stantially to this number [1]. Clear information on the* Correspondence: j.schuling@umcg.nl
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reproduction in any medium, provided the oreffects of these combined therapies in elderly patients is
often lacking [2]. The respective risk reductions found in
clinical trials are probably not strictly cumulative, and
the benefits to these elderly patients will be less than the
sum of the ‘single’ therapies [3]. The number of drugs,
however, may burden patients and enhance the risk of
adverse drug events (ADEs). Polypharmacy is associated
with increased non-adherence to prescribed medica-
tions, as well as with diverse outcomes such as malnutri-
tion, functional impairment, falls and fractures,
hospitalization and institutionalization [4,5].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as unavoidable [6] but elderly patients can also have un-
voiced concerns about the need to take all their medica-
tion [7]. They value some drugs as being more important
than others [8] but also differ in their preferences for in-
tensive treatment [9]. Their health goals focus more on
quality of life than on extending their lives [10]. In view
of the limited life expectancy of many of these older
patients, stopping medication meant for prevention may
relieve symptoms perceived as ADEs, and thus improve
the patient’s wellbeing. To support doctors in their man-
agement of polypharmacy in the elderly, two kinds of
expert-driven instruments have been developed. Firstly,
there are several protocols for reviewing medication
using criteria for drug and patient characteristics, such as
comorbidity and pharmacodynamics [11]. Secondly, a
normative model has been developed for good prescrip-
tion practices for elderly patients [12]
Thus far, these medication-centred tools, which have
been developed from the expert’s point of view, have
demonstrated little effect on patient outcomes, in par-
ticular on mortality or quality of life [13]. As this latter
goal is the most important for patients late in life, physi-
cians should focus on patient preferences to improve
quality of life [14]. This is also emphasized by Holmes
who points out how treatment targets and goals of care
for the individual patient should be adapted over time
according to the preferences of the patient and his life
expectancy [12].
In recent years, much attention has been paid to
shared decision-making in general practice, mainly fo-
cusing on patient preferences [15]. In diabetes care it
has been found that patients and their doctors generally
differ in treatment goals [16], but no attention has been
paid to how such issues affect decisions to stop treat-
ment for the very elderly.
This study explores how experienced GPs feel about
deprescribing medication in older patients with multi-
morbidity and to what extent they involve patients in
these decisions.
Methods
We chose a qualitative study design as data about depre-
scribing medication in elderly patients by GPs are lack-
ing sofar. A small group meeting of peers seemed the
best setting to create a non-judging atmosphere in which
the GPs would stimulate and inspire each other to ex-
change their views and experiences with this issue. A
focus group can provide such a climate. On basis of
these conversations we intended to develop a conceptual
framework for understanding and categorizing GPs’
views on the subject.
We organized focus groups of GPs with a minimum of
five years experience and active as GP trainers. We thusensured that our participants had sufficient exposure to
the relevant problems and as GP trainers were used to
reflecting on their daily practice routines.
GP trainers with a third-year trainee in their practice
at the time of the study were invited by the department
of vocational training for general practice to participate
in the study. Recruitment of participants continued until
saturation was reached.
In December 2010 and January 2011 three focus
groups were organized in which 12, 9 and 8 GPs partici-
pated, respectively. By the third focus group, most of the
issues that were being raised had already been men-
tioned, and it was decided that little was to be gained
from continuing data collection, in other words that sat-
uration was reached.
Having read the study protocol the secretary of the
medical ethical board of the University Medical Center
Groningen gave the advice not to seek a formal ethical
approval of the committee on grounds of efficiency, as
the participating GPs were asked to give their explicit
consent to the anonymous publication of the data at the
end of a meeting.
Before starting, participants completed a brief ques-
tionnaire on demographic and practice characteristics.
The groups were led by a moderator (HJG) with one ob-
server (JS). At the start of the meeting the focus group
moderator presented a hypothetical profile of a very eld-
erly patient with multimorbidity and her guideline-
driven list of medication (Table 1). This example was
used to help participants to remember their own similar
patients. The moderator outlined the position of the GP
balancing between the risks of polypharmacy, the vul-
nerability of elderly patients and the guidelines involved
recommending prescribing. Participants were encour-
aged to share their views and experiences on the possi-
bilities for reducing the medication of their patients.
When necessary, question probes were used to elicit
discussion on key topic areas such as the elements of
the Holmes model (life expectancy, treatment targets,
goals of care and time until benefit) that did not emerge
spontaneously in the conversation.Data analysis and intersubjectivity
The focus group meetings were held at the Department
of General Practice of the University Medical Center
Groningen. The meetings lasted about 2 hours and were
audiotaped. The tapes were transcribed verbatim. These
manuscripts were read by the first and second author,
who independently selected relevant text fragments.
They then labelled these fragments and sorted them.
Central themes were extracted from these labelled and
sorted fragments. When the two researchers could not
agree, the issue would be presented to the third author
Table 1 Fictitious profile of a very elderly patient with
multimorbidity
• Alendronate tab 70 mg q1w
• Calciumcarb/colecalcif 500 mg/400IE BID
• Acetylsalicyl tab 80 mg OD
• Dipyridamol caps mga 200 mg BID
• Enalapril tab 10 mg OD
• Gliclazide tab mga 30 mg OD
• HydroChloroThiazide tab 12.5 mg OD
• Metformin tab 500 mg TID
• Metoprolol tab mga 50 mg OD
• Macrogol 2dd1 BID
• Paracetamol tab 500 mg TID
• Ranitidine tab 150 mg BID
• Salmeterol inhal 50 mcg BID
• Simvastatine tab 40 mg OD
• Spironolacton tab 25 mg OD 0.5
• Tiotropium inhal 18 mcg OD
• Temazepam tab 10 mg OD
The file of Mrs van Kampen, an 83-year-old widow living independently, lists
the following problems: CVA, radius fracture, osteoporosis, diabetes mellitus
type II, COPD (Gold III), hypertension, heart failure (NYHA III), gastro
oesophageal reflux, degenerative arthritis in one knee, dizziness, sleeping
problems and constipation.
Her medication list includes 17 drugs, prescribed in accordance with the
relevant current disease specific guidelines.
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Results
Characteristics of participants
Of the participants, two were female and the mean age
was 54 (range 39–65); 13 practices were located in a city,
9 practices in the countryside and 7 practices in be-
tween. All participants were practising in the northern
three provinces of the Netherlands.
During the process of analysing the transcripts and
labelling fragments non-agreement between the two
researchers did not occur. The following themes were
grouped into three domains:
1. Beliefs of the GPs concerning, best practice, patients
and medication
2. Knowledge and skills of the GPs
3. Guidelines for treatment and organization of
healthcare
Beliefs of the GPs
In general, GPs report to support the concept of a
patient-centred management as best practice. Respect
for values and beliefs of the patient are a compass fortheir management. Discussing drug therapy with their
patients, they see it as their duty to provide necessary in-
formation on possible treatment choices and their re-
spective outcomes.
– Above all you should provide sufficient information
to enable people to make a choice. Honest and
good information.
– Let people choose for themselves however. Not based
on emotions but numbers. Explain it with
percentages.
In practice, however, they experience a number of pro-
blems with actually addressing the issue of deprescribing
medication. Based on their experience, they consider
that their patients have no problem with polypharmacy,
or with medication burden,
– The discontent rarely lies with old people themselves.
but on the other hand they are aware of the importance
to know how a patient values his medication
– I think that it’s important how people themselves look
onto their medication.
Some GPs indicate that patients appear to cling to
their extensive medicationlist.
– ..some patients love all those drug, to show off to
their neighbours.’ You know what mass I have to take
each day?’
Nonetheless, the GPs acknowledge that they may not
be fully aware of the actual problems patients experi-
ence. In the GPs’ view, patients underreport possible
ADEs, attributing these symptoms to old age rather than
to their medication.
– They accept these symptoms, they are part of their
aging.
In addition, patients may report their symptoms to
other healthcare professionals, for example, to the med-
ical specialist, nurse practitioners or specialist nurses.
Moreover, GPs are reluctant to initiate a discussion about
stopping medication because they are concerned that
patients may interpret this as a sign of being given up on.
– People may then get the feeling, ‘Don’t I count
anymore, am I not important?’
The GPs hesitate to discuss the subject of life expect-
ancy with their patients.
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patient.
On the other hand some participants report how
patients spontaneously talk about their limited life
expectancy.
– ‘What ‘s left for me, is limited.’
– ‘Well doc, when it’s over tomorrow, that’s OK with
me’.
Some GPs think that confronting a patient with a dis-
cussion about life expectancy versus quality of life is
not ethical. At the same time, however, others report
that a discussion with their patient about the quality of
the patient’s remaining lifetime had a positive effect on
their relationship.
Participants vary in their belief on the effects of pre-
ventive drug therapy in elderly patients. Some state that
the benefit of preventive medication for the individual
patient is small, but at a population level worthwile.
– I think these (ARR) numbers are low; these numbers
are disappointing.
Finally, some GPs mention patient characteristics as a
barrier to the patient’s understanding of the issue.
– Low education and old age means it is more difficult
to discuss these matters.
Knowledge and skills
Confronted with multimorbidity and its ensuing pro-
blems GPs experience difficulties in identifying ADEs,
and take the patient’s judgement in this matter seriously.
– Which drugs do you think are responsible? Patients
are mostly right.
During the meetings it became clear that there is an
obvious difference for GPs between stopping medication
on account of symptoms and intervening in long-term
preventive medication. Participants felt competent in
symptom management, stopping medication when symp-
toms are cured or relieved. For chronic problems, the
symptomatic medication was tailored to an optimum as
indicated by the patient’s feedback. Preventive medica-
tion, however, did not offer such a compass. The real area
of concern for the participants was how to manage the
long-term use of preventive medication.
– In my view there’s a big difference between drugs
meant for prevention and the drugs that are really
therapeutic.– I focus first on preventive medication: which drug is
really indicated?
The problem of the lack of evidence of the effects of
preventive medication in the very elderly is paramount
– With a 40 year old, I’m fairly confident deciding on
what medication to prescribe. But I notice I’m less
certain with an 80 year old.
– I take her quality of life into account and ask myself
will she live long enough to benefit from this
(preventive) drug?
GPs indicate a strong need for clear information on
the benefit/risk ratio of preventive medication in the
very old and often frail.
– Giving the patient real choices, providing information
is very useful. For instance, by putting ARR numbers
on the package.
Even if such information were available, some partici-
pants feel incompetent in risk communication, and
others consider this information not helpful for actual
shared decision-making.
– We can’t predict the effect for the individual patient.
– The coloured numbers in the cardiovascular risk
tables of our guideline have an important effect:
when your patient sees himself land in orange or red
his motivation is influenced.
All participants admit they were seldom aware of their
patients’ treatment preferences.
Where some participants express problems with
explaining the tension between quality and length of life,
– An elderly person stands up, feels dizzy as hell,
but he may live a little longer. Well, these matters
I discuss.
others emphasize the option of taking a positive ap-
proach to stopping preventive medication.
– You can have a field day with crossing off
medication: ‘sure, scrap half of it’.Guidelines and organization of healthcare
Another important group of barriers concerns the
current guidelines. GPs feel forced by current guidelines
to prescribe many different medicines: they appear to
pile the recommendations of one guideline on another
instead of prioritizing.
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moment they do not cater for older patients.
Participants claim they often feel guilty when their ad-
herence to guidelines is not up to scratch.
– I have difficulty not following the guidelines if I don’t
have good reasons to do so.
A new patient entering the practice list is welcomed as
an opportunity to review their medication. Some GPs
complain about an inadequate overview of the patient’s
medication.
– The problem is that the medication lists of the
doctors involved are not exchanged and are
consequently inconsistent.
In multimorbidity, several healthcare providers are
involved in a patient’s treatment and communication is
sometimes poor. Cooperation with prescribing medical
specialists who represent ‘their’ guideline is the next im-
portant barrier to deprescribing medication.
– All doctors should speak with one voice. Different
stories provoke distrust.
In addition, most GPs work closely with a local
pharmacist: the task perception of such pharmacists was
an important factor when a GP was looking for decision
support in medication review.
Discussion
The participants expressed great commitment to the
problems discussed and qualified this issue as highly
relevant for general practice. Although they were enthu-
siastic to contribute to the discussion, their feelings with
regard to their management of the problem ranged from
moderate optimism to something close to despair. The
latter was illustrated by GPs expressing strong concerns
about the wellbeing of their elderly patients, but feeling
unable to do anything about the medication.
Summary of main findings
This study reveals a range of factors affecting the GPs’
deprescribing for elderly patients with multimorbidity.
The GPs discern symptomatic and preventive medica-
tion; deprescribing the latter category is seen as more
difficult by the GPs due to lack of benefit/risk informa-
tion for these patients.
Our findings suggest that GPs tend to avoid discussing
withdrawal of preventive medication with their elderly
patients. Their beliefs concerning patients support, even
justify, this policy. Although the GPs are in favour of apatient-centred approach, they do not inquire into the
patients’ preferences or discuss treatment goals.
The GPs indicate a strong need for better information
on the benefit/risk ratio for preventive medication in the
very elderly. Current guidelines are overly focused on
the management of a single disease and do not take into
account the problem of multimorbidity. The problem is
aggravated by the involvement of several medical specia-
lists, who each emphasize the importance of ‘their’
guideline. Prioritization is clearly needed but GPs do not
feel empowered to do so. It is however doubtful that
managing polypharmacy of elderly patients with multi-
morbidity can be completely ‘covered’ by guidelines in
view of the heterogeneity of patient characteristics. This
underlines the necessity of patient involvement as
described in the model of Holmes. The concept of
shared decision making provides an important and use-
ful framework to put this model into practice [17].
The GPs’ beliefs about best-practice support manage-
ment favouring shared decision-making. Apparently
there is a discrepancy between this belief in best practice
and the actual management of the problem.
Strengths and weaknesses
Our respondents are not a representative sample of
Dutch GPs but a rather homogeneous group of older
male GPs. We purposively sampled experienced GPs to
ensure sufficient exposure to the theme of this study.
The GPs in these focus groups showed a strong involve-
ment with the problem although there was no agree-
ment on the weight attached to the factors that were
brought up. In view of the growing population of older
patients we don’t expect less involvement among Dutch
GPs in general. In our opinion younger GPs tend to fol-
low the guidelines more strictly. Younger GPs whose
working alliance with their patient has a shorter history
may have more difficulty in anticipating preferences of
the patient.
Comparison with existing literature
Our participants did not bring up non-adherence to
complex treatment regimes as a factor influencing their
management, but they did struggle with the uncertain-
ties of applying disease specific guidelines to their elderly
patients as described by Fried [18]. Their need for better
outcome data and the complicating role of prescribing
subspecialists was evident.
Aiming for optimal quality of life for the very elderly
GPs need the tools of shared decision-making to achieve
this goal [17]. Although this emphasizes the importance
of exploring patient preferences about treatment goals,
in practice GPs appear hesitant. Such reluctance could
be overcome by tailoring the training of care providers
in communication competences [19]. In particular, GPs
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issues and the length of time to see benefits when con-
sidering the pros and cons of preventive medication.
Allthough some studies have shown that more than half
of the patients are willing to discuss life expectancy [20-
22], others report that many seriously ill patients and
caregivers may not be ready or able to receive prognostic
information [23]. However the number of studies is lim-
ited and concerns younger patients in a different setting.
Our study focuses on settings that offer an opportunity
for discussion on ‘modification of targets for chronic dis-
ease management’ and ‘reducing burden of medication’
or ‘life choices’ [21]. Patients as well as caregivers indi-
cated that they would use a shared decision making in-
strument in clinical encounters and attributed multiple
functions to the instrument, especially as a tool to facili-
tate agreement on treatment goals and plans [24]. Such
a simple tool to elicit patient preferences has been devel-
oped and looks promising, but questions about its reli-
ability still need to be answered [25].
Providing information to patients about possible harm
and benefits appeared to increase the knowledge of
patients and to reduce their decisional conflict, but it
had no consistent effect on patient’s decision to start or
continue drug treatment [26].
Doctors have several explicit reasons for not prescrib-
ing according to guidelines in older patients, such as pa-
tient preferences, adverse events, non-adherence and
patient benefit, but these studies implicitly refer to start-
ing new medication [27]. Intervening in long-term pre-
ventive medication is quite another issue, as our results
show. The finding that antihypertensive agents can be
stopped in elderly patients without harm to them may
encourage GPs to seriously consider stopping preventive
medication [28].
Conclusions
Our study is a first exploration of GP perceptions of
deprescribing. More generalizable information is required
to develop tools that could support GPs when reviewing
medication of elderly patients with multimorbidity.
The GPs appear to adhere to multiple guidelines in
the absence of a practical tool for prioritization accord-
ing to patient preferences elderly patients are quite cap-
able of prioritizing outcomes [29]. Such prioritization is
essential, as the available expert systems are not suffi-
cient to achieve improvement in quality of life of the
elderly patients. The variability in individual priorities
underlines the need to elicit individual preferences in a
context of shared decision-making. Our results confirm
previous findings concerning the need for clear and ac-
cessible data on the benefits and risks of treatment
options caregivers experience. Such information is a pre-
condition for shared decision-making.Implications for future research
The results of our study need to be quantified in a more
representative sample of GPs and other healthcare pro-
fessionals actively involved in treating the frail elderly.
Confirmation of our findings will contribute to the devel-
opment of strategies to overcome the barriers found in
this study, with a focus on the training of GPs and their
staff. Such project should include the following steps:
1. Training to elicit patient preferences with a tool as
described by Fried as a start of medication
reviewing. Examples of how a care provider can
discuss the option of withdrawal of preventive
medication with their patients can be shown and
will help to overcome the barriers described above.
2. Training how to translate these patient preferences
in congruent changes of the patient’s current
treatment.
3. Monitoring the effects of this patient driven
medication review on the patient’s wellbeing.
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